OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud

Oculis Holding AG shares lost over 23% of their value in a single session after Phase 3 DIAMOND trial results revealed OCS-01 failed to meet its primary endpoint in diabetic macular edema.

NEW YORK--(BUSINESS WIRE)--Shareholders of Oculis Holding AG (NASDAQ: OCS) lost nearly $7 per share, more than 23%, in a single trading session when the company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint -- mean change in best-corrected visual acuity at week 52 -- in diabetic macular edema. Oculis simultaneously announced it would not pursue an FDA filing for the DME indication. Investors who lost money on OCS are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

The approximately 23.4% single-day decline followed disclosure that OCS-01 eye drops -- the company's lead pipeline candidate targeting what Oculis had described as a multi-billion-dollar market -- did not achieve statistical significance on the primary efficacy measure across both pivotal trials. The company stated it would redirect resources to other pipeline candidates and would not file a New Drug Application for the DME indication.

Prior to the disclosure, Oculis had described the DIAMOND program as positioned for topline results in 2026 with a subsequent NDA submission planned for Q4 2026. CEO Sherif had previously claimed it was a product they “know that it works … really the only risk … is execution.” Despite their claimed “obsessive execution,” the studies ultimately failed and the stock's 23% decline erased hundreds of millions of dollars in market capitalization in a single session.

Shareholders who purchased OCS and suffered a loss are encouraged to click here to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities investigations and recoveries. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the OCS Investigation

Q: Who is eligible to participate in the OCS investigation? A: Investors who purchased OCS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did OCS stock drop? A: Shares fell approximately 23% in a single trading session after the company disclosed that Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint in diabetic macular edema and announced it would not pursue an FDA filing for that indication.

Q: What do OCS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [e-mail] or [phone]. No immediate action is required to remain eligible to participate in the investigation.

Q: What if I already sold my OCS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought OCS and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. The overwhelming majority of affected investors never appear in court.